Escudero-Vilaplana Vicente, Romero-Medrano Lorena, Villanueva-Bueno Cristina, Rodríguez de Diago Marta, Yánez-Montesdeoca Alberto, Collado-Borrell Roberto, Campaña-Montes Juan José, Marzal-Alfaro Belén, Revuelta-Herrero José Luis, Calles Antonio, Galera Mar, Álvarez Rosa, Herranz Ana, Sanjurjo María, Artés-Rodríguez Antonio
Pharmacy Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
Front Oncol. 2022 Jul 13;12:880430. doi: 10.3389/fonc.2022.880430. eCollection 2022.
We have defined a project to develop a mobile app that continually records smartphone parameters which may help define the Eastern Cooperative Oncology Group performance status (ECOG-PS) and the health-related quality of life (HRQoL), without interaction with patients or professionals. This project is divided into 3 phases. Here we describe phase 1. The objective of this phase was to develop the app and assess its usability concerning patient characteristics, acceptability, and satisfaction.
The app eB2-ECOG was developed and installed in the smartphone of cancer patients who will be followed for six months. Criteria inclusion were: age over 18-year-old; diagnosed with unresectable or metastatic lung cancer, gastrointestinal stromal tumor, sarcoma, or head and neck cancer; under systemic anticancer therapies; and possession of a Smartphone. The app will collect passive and active data from the patients while healthcare professionals will evaluate the ECOG-PS and HRQoL through conventional tools. Acceptability was assessed during the follow-up. Patients answered a satisfaction survey in the app between 3-6 months from their inclusion.
The app developed provides a system for continuously collecting, merging, and processing data related to patient's health and physical activity. It provides a transparent capture service based on all the available data of a patient. Currently, 106 patients have been recruited. A total of 36 patients were excluded, most of them (21/36) due to technological reasons. We assessed 69 patients (53 lung cancer, 8 gastrointestinal stromal tumors, 5 sarcomas, and 3 head and neck cancer). Concerning app satisfaction, 70.4% (20/27) of patients found the app intuitive and easy to use, and 51.9% (17/27) of them said that the app helped them to improve and handle their problems better. Overall, 17 out of 27 patients [62.9%] were satisfied with the app, and 14 of them [51.8%] would recommend the app to other patients.
We observed that the app's acceptability and satisfaction were good, which is essential for the continuity of the project. In the subsequent phases, we will develop predictive models based on the collected information during this phase. We will validate the method and analyze the sensitivity of the automated results.
我们已确定一个项目来开发一款移动应用程序,该程序可持续记录智能手机参数,这可能有助于定义东部肿瘤协作组体能状态(ECOG-PS)和健康相关生活质量(HRQoL),且无需与患者或专业人员互动。该项目分为三个阶段。在此我们描述第一阶段。此阶段的目标是开发该应用程序,并评估其在患者特征、可接受性和满意度方面的可用性。
开发了应用程序eB2-ECOG并安装在将被随访六个月的癌症患者的智能手机中。纳入标准为:年龄超过18岁;被诊断为不可切除或转移性肺癌、胃肠道间质瘤、肉瘤或头颈癌;正在接受全身抗癌治疗;且拥有智能手机。该应用程序将从患者那里收集被动和主动数据,而医疗专业人员将通过传统工具评估ECOG-PS和HRQoL。在随访期间评估可接受性。患者在纳入后的3至6个月内通过应用程序回答了满意度调查。
所开发的应用程序提供了一个用于持续收集、合并和处理与患者健康和身体活动相关数据的系统。它基于患者的所有可用数据提供透明的捕获服务。目前,已招募了106名患者。共有36名患者被排除,其中大多数(21/36)是由于技术原因。我们评估了69名患者(53例肺癌、8例胃肠道间质瘤、5例肉瘤和3例头颈癌)。关于应用程序满意度,70.4%(20/27)的患者认为该应用程序直观且易于使用,其中51.9%(17/27)的患者表示该应用程序帮助他们更好地改善和处理问题。总体而言,27名患者中有17名[62.9%]对该应用程序满意,其中14名[51.8%]会向其他患者推荐该应用程序。
我们观察到该应用程序的可接受性和满意度良好,这对项目的连续性至关重要。在后续阶段,我们将基于此阶段收集的信息开发预测模型。我们将验证该方法并分析自动结果的敏感性。